基线18F-FDG PET/CT小脑/肝脏摄取比值(CLIP)改善移植后淋巴增殖性疾病预后判断:一项多中心回顾性研究
本研究为多中心回顾性研究,纳入K-VIROGREF队列中97例移植后淋巴增殖性疾病(PTLD)患者,评估基线18F-FDG PET/CT小脑/肝脏摄取比值(CLIP)对无进展生存期(PFS)和总生存期(OS)的预后价值,采用既往发表的CLIP阈值3.24。结果显示IPI评分≥3和CLIP<3.24均为PFS的显著危险因素,CLIP对OS未达统计学显著(HR 2.6,P=0.059)。作者认为CLIP是PFS有前景的预测指标,可能对OS也有预测价值,需进一步前瞻性研究确认。
要点
- CLIP对OS未达统计学显著(HR 2.6,P=0.059),IPI评分和总代谢肿瘤体积对OS均未达显著。
核心结论
- CLIP是PTLD患者PFS有前景的预测指标,可能对OS也有预测价值,需进一步前瞻性研究确认。
研究设计与样本
- 多中心回顾性研究,基于K-VIROGREF队列纳入97例PTLD患者,采用既往发表的CLIP阈值3.24进行分析。
主要发现
- 97例患者中单形性弥漫大B细胞淋巴瘤亚型占78.3%。
- CLIP对OS未达统计学显著,HR 2.6(P=0.059)。
- IPI评分和总代谢肿瘤体积对OS均未达统计学显著。
关键数值与推荐
- CLIP对OS的HR为2.6(P=0.059),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步前瞻性研究确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Besides International Prognostic Index (IPI) score, baseline prognostic factors of post-transplant lymphoproliferative disorders (PTLD) are poorly identified due to the rarity of the disease. New indexes derived from healthy organ uptake in baseline 18F-FDG PET/CT have been studied in immunocompetent lymphoma patients. The aim of this study is to evaluate the performances of the cerebellum-to-liver uptake ratio (denoted as CLIP) as a prognostic factor for PFS and OS. This retrospective multicenter study is based on patients with PTLD included in the K-VIROGREF cohort. The previously published threshold of 3.24 was used for CLIP in these analyses. RESULTS: A total of 97 patients was included with a majority of monomorphic diffuse large B-cell lymphoma subtype (78.3%). Both IPI score (≥ 3) and CLIP (< 3.24) were significant risk factors of PFS with corresponding hazard ratios of 2.0 (1.0-4.0) and 2.4 (1.3-4.5) respectively. For OS, CLIP was not significant and resulted in a hazard ratio of 2.6 (p = 0.059). Neither IPI score or Total Metabolic Tumor Volume reached significance for OS. CONCLUSION: CLIP is a promising predictor of PFS and perhaps OS in PTLD. Further prospective studies are needed to confirm these results.
引用
- Morland D, Kanagaratnam L, Hubelé F, et al. Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study. EJNMMI Res. 2024. PMID: 38801646. doi:10.1186/s13550-024-01111-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。